Genetron Health's Self-Developed Mutation Capsule Differentiates It From Others

  • Genetron Health's impressive performance also results from its double-track operation mode.
  • Genetron Health specializes in molecular cancer profiling. While the global cancer treatment market is still immature, the company has harnessed the valuable development opportunity.   
  • The global population has had higher overall cancer incidence rates in recent years, directly stimulating the rising cancer diagnostics market. This medical company increased its  R&D expenses and focused on creating a circulating tumor DNA (ctDNA) diagnosis method to improve its market competitiveness.
  • But the company still encounters major challenges from other top players, China's economic issues, and the wholly immature market.

Genetron Health has lately attracted increasing attention from investors. Consequently, it went public on Nasdaq in June 2020, raising a total of USD 0.26 billion, which is the largest to date IPO in the precision medicine sector of the global cancer treatment market. After this IPO, the medical company's share prices fluctuated but presented an upward trend in general, with a peak of USD 30.64 in early February 2021. 

Founded in 2013, Genetron Health (GTH) started its businesses by conducting brain tumor research and product development. Based on molecular biology and extensive data analysis, the firm developed a comprehensive product and service line, including early cancer screening, treatment recommendation, monitoring, and prognosis management. In 2021 spring's early cancer screening seminar hosted by Science magazine, the firm introduced its Mutation Capsule technology that can capture cell-free DNA's methylation and mutation simultaneously.

COVID-19 did not affect Genetron Health's profitability

2020 was a significant year for Genetron Health that saw it achieve good performance in its three main sectors, even during the outbreak of COVID-19. The company achieved a YoY growth rate of about 31.3%. To be more precise, it generated 72.01% of the total revenue from laboratory-developed test (LDT), appearing as the most prominent business segment in the last few years. However, the in vitro diagnostics (IVD) segment showed the highest increase rate in the past few years, with an average of 31.65%. 

1 2 3 4
View single page >> |

Disclaimer: Please consult your own advisor before making any investment decision. 

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.